bioAffinity Reports 100% Growth in CyPath Lung Sales for Q3 2026

Key Facts

1bioAffinity Technologies announced that sales of its CyPath Lung test increased by more than 100% through Q3 2026 compared to 2025.

bioAffinity Technologies announced that sales of its CyPath Lung test increased by more than 100% through the third quarter of 2026 compared to the previous year. According to a statement reported by Business Wire, the growth was driven by increased clinical adoption of the company's diagnostic solutions for high-risk individuals.

BIAF closed at $6.19 on October 5, 2026, with the stock reaching a day high of $6.2 and a low of $5.85 during the session. The surge in sales reflects the company's continued expansion in the healthcare market through its noninvasive lung cancer detection technology.